Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756393 | 0.89 | GPR142 (0.38) | GPR142MGLLBRD4CREBBPWNT1 | |
| SCHEMBL782217 | 0.85 | GPR119 (0.38) | GPR119USP30GPR142PIK3CDRAF1 | |
| SCHEMBL781918 | 0.83 | FAAH (0.39) | USP30GPR142 | |
| SCHEMBL782067 | 0.82 | BACE1 (0.38) | USP30GPR142MGLLRAF1BRAF | |
| SCHEMBL782015 | 0.82 | GPR119 (0.38) | GPR119USP30PIK3CDPIM1 | |
| SCHEMBL781929 | 0.81 | LMNA (0.43) | GPR119 | |
| SCHEMBL781904 | 0.79 | GRIA2 (0.40) | GPR119GPR142MGLL | |
| SCHEMBL782099 | 0.78 | MAPT (0.39) | — | |
| SCHEMBL782225 | 0.77 | LMNA (0.47) | GPR119SCD5 | |
| SCHEMBL783237 | 0.75 | TDP1 (0.42) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | GPR119 164/4885USP30 2228/4885GPR142 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.